Date: 2017-12-15
Type of information: Licensing agreement
Compound: Cx601 (adipose derived allogeneic stem cell therapy)
Company: Mesoblast (Australia) Tigenix (Belgium)
Therapeutic area:
Type agreement: licensing
Action mechanism:
- Cell therapy. Cx601 is a suspension of expanded allogeneic adult stem cell (eASCs) product derived from human adipose (fat) tissue (expanded Adipose derived Stem Cells or eASCs) that is delivered locally in the fistula through intra-lesional injection. Cx601 is currently in Phase III of clinical development for the treatment of complex perianal fistulas in patients with Crohn's disease.
- Cx601 has been licensed to Takeda for the exclusive development and commercialization outside the US.
Disease:
Details:
- • On December 15, 2017, Mesoblast and TiGenix announced that Mesoblast has granted TiGenix exclusive access to certain of its patents to support global commercialization of the adipose-derived mesenchymal stem cell product Cx601 for the local treatment of fistulae. The agreement includes the right for TiGenix to grant sub-licenses to affiliates and third parties, including TiGenix's current development and commercialization partner ex-United States.
- Mesoblast continues to develop its proprietary bone marrow-derived allogeneic expanded MSC product candidate for intravenous delivery to induce remission in patients with biologic-refractory Crohn's disease.
Financial terms:
- As consideration, Mesoblast will receive up to €20 million (approximately $24 million) in payments, with €5 million upfront, €5 million within 12 months, and up to €10 million in product regulatory milestones. Additionally, Mesoblast will receive single digit royalties on net sales of Cx601.
Latest news:
Is general: Yes
